Loading ticker data...
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | Gould Robert J | - | Sell | 15,000 | $11.87 | $178,089.00 | -3.1% | → |
| 2025-12-15 | Oltmans Curtis Gale | Chief Legal Officer | Sell | 3,452 | $12.92 | $44,599.84 | -25.2% | → |
| 2025-12-08 | RA CAPITAL MANAGEMENT, L.P. | - | Sell | 4,175,139 | $13.98 | $58,377,021.32 | -16.6% | → |
| 2025-11-19 | Gould Robert J | - | Sell | 15,000 | $11.03 | $165,495.00 | -3.0% | → |
| 2025-05-08 | Tourangeau Greg | Principal Accounting Officer | Sell | 498 | $5.06 | $2,519.88 | -3.4% | → |
| 2024-05-07 | Tourangeau Greg | Principal Accounting Officer | Sell | 236 | $7.76 | $1,831.36 | -2.0% | → |
| 2024-03-08 | Tourangeau Greg | Vice President, Finance | Sell | 4,884 | $11.72 | $57,218.50 | -29.3% | → |
| 2024-03-04 | Sapir Alex | See Remarks | Buy | 43,360 | $11.35 | $492,027.60 | New | → |
| 2023-05-10 | Tourangeau Greg | Principal Accounting Officer | Sell | 210 | $3.31 | $695.10 | -1.3% | → |
| 2023-01-20 | RA CAPITAL MANAGEMENT, L.P. | - | Buy | 1,923,076 | $13.00 | $24,999,988.00 | +19.9% | → |
| 2023-01-13 | Gould Robert J | Interim President & CEO | Sell | 6,766 | $15.00 | $101,490.00 | -1.3% | → |
| 2023-01-04 | RA CAPITAL MANAGEMENT, L.P. | - | Buy | 180,703 | $7.28 | $1,314,805.84 | +0.9% | → |
| 2022-12-27 | RA CAPITAL MANAGEMENT, L.P. | - | Buy | 4,089 | $5.99 | $24,509.87 | - | → |
| 2022-12-19 | RA CAPITAL MANAGEMENT, L.P. | - | Buy | 98,787 | $5.90 | $582,813.66 | +1.1% | → |
| 2022-12-16 | RA CAPITAL MANAGEMENT, L.P. | - | Buy | 2,403,049 | $5.44 | $13,073,873.91 | +10.5% | → |
| 2022-06-07 | Gould Robert J | Director | Sale+OE | 71,435 | $8.09 | $577,894.86 | -12.4% | → |
| 2022-06-06 | Gould Robert J | Director | Sale+OE | 66,622 | $8.00 | $532,809.94 | -4.2% | → |
| 2022-04-07 | Gould Robert J | Director | Sale+OE | 5,631 | $24.02 | $135,228.47 | -1.1% | → |
| 2022-04-05 | Gould Robert J | Director | Sale+OE | 94,251 | $24.16 | $2,276,683.71 | -5.8% | → |
| 2021-08-11 | Stuart Bryan | See Remarks | Sale+OE | 60,000 | $20.42 | $1,225,000.00 | -100% | → |
| 2021-08-10 | Moxham Christopher | Chief Scientific Officer | Sale+OE | 51,785 | $17.60 | $911,416.00 | -100% | → |
| 2021-06-28 | Morabito Christopher | Chief Medical Officer | Buy | 1,100 | $9.16 | $10,076.00 | New | → |
| 2021-06-28 | Oltmans Curtis Gale | SVP, General Counsel | Buy | 1,088 | $9.01 | $9,802.88 | New | → |
| 2021-06-28 | Thomson Peter G. | VP Finance & Accounting | Buy | 2,300 | $9.00 | $20,700.00 | New | → |
| 2021-06-28 | GERAGHTY JAMES A | Director | Buy | 10,000 | $9.16 | $91,600.00 | +12.4% | → |
| 2021-03-16 | Gould Robert J | See Remarks | Sell | 10,000 | $12.16 | $121,578.33 | -1.0% | → |
| 2021-02-22 | Thomson Peter G. | VP Finance & Accounting | Sale+OE | 5,000 | $14.72 | $73,581.50 | -24.7% | → |
| 2021-02-16 | Gould Robert J | See Remarks | Sell | 8,215 | $14.27 | $117,197.40 | -0.8% | → |
| 2021-01-21 | Thomson Peter G. | VP Finance & Accounting | Sell | 6,607 | $14.00 | $92,498.00 | -30.3% | → |
| 2021-01-20 | Gould Robert J | See Remarks | Sell | 10,000 | $12.08 | $120,826.00 | -1.9% | → |
| 2020-07-08 | Wallace Owen B. | Chief Scientific Officer | Sale+OE | 2,951 | $20.00 | $59,020.00 | -2.3% | → |
| 2020-07-08 | Gould Robert J | See Remarks | Sell | 2,500 | $20.00 | $50,000.00 | -0.5% | → |
| 2020-07-01 | Cadavid Diego | SVP Clinical Development | Sell | 1,071 | $18.30 | $19,599.30 | -1.6% | → |
| 2020-06-30 | Wallace Owen B. | Chief Scientific Officer | Sale+OE | 141 | $20.00 | $2,820.00 | -0.1% | → |
| 2020-06-25 | Cadavid Diego | SVP Clinical Development | Sale+OE | 1,459 | $22.00 | $32,098.00 | -2.1% | → |
| 2020-06-25 | Gould Robert J | See Remarks | Sell | 2,500 | $20.80 | $51,992.00 | -0.5% | → |
| 2020-06-10 | Cadavid Diego | SVP Clinical Development | Sale+OE | 401 | $22.00 | $8,822.00 | -0.6% | → |